EVMN · NYSE · Biotechnology

Evommune (EVMN)

Develops chronic-inflammation therapies centered on EVO756 and EVO301 clinical programs.

$9.70
After-hours close+0.11 (+1.15%)
At close$9.59(+1.48%)

Something off on this page? Send us feedback.

Next report
Oct 16, 26
in 24 days
EPS estimate
−$0.82
Revenue estimate
$333.3K
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Oct '25Dec '25Mar '26May '26Aug '26Oct '26
Reported−$0.45−$8.07−$1.43−$0.64−$0.89Pending
Estimate−$6.08−$0.84−$0.82−$0.83−$0.66−$0.82
Surprise+92.6%−858.4%−74.4%+22.9%−33.9%

RevenueReportedEstimate

Oct '25Dec '25Mar '26May '26Aug '26Oct '26
Reported$10.0M$0Pending
Estimate$3.3M$3.3M$722.2K$722.2K$1.3M$333.3K
Surprise+200.0%−100.0%

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Dec 2028−$0.85
Sep 2028−$0.90
Jun 2028−$0.86
Mar 2028−$0.86
Dec 2027−$1.10
Sep 2027−$1.05
Jun 2027−$1.01
Mar 2027−$0.98
Dec 2026−$0.90
Oct 2026−$0.82
Aug 2026−$0.66−$0.89−33.9%
May 2026−$0.83−$0.64+22.9%
Mar 2026−$0.82−$1.43−74.4%
Dec 2025−$0.84−$8.07−858.4%
Oct 2025

The latest year is open to everyone — the 1 quarter behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2028−$0.85$0
Sep 2028−$0.90$0
Jun 2028−$0.86$0
Mar 2028−$0.86$0
Dec 2027−$1.10$0
Sep 2027−$1.05$0
Jun 2027−$1.01$0
Mar 2027−$0.98$0
Dec 2026−$0.90$3.3M
Oct 16, 2026−$0.82$333.3K
Aug 6, 2026−$0.66−$0.89−33.9%$1.3M$0−100.0%+5.2%
May 7, 2026−$0.83−$0.64+22.9%$722.2K−5.6%
Mar 5, 2026−$0.82−$1.43−74.4%$722.2K+6.4%
Dec 11, 2025−$0.84−$8.07−858.4%$3.3M$10.0M+200.0%+0.4%
Oct 9, 2025

The latest year is open to everyone — the 1 quarter behind it read with an account.